Skip to content

An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children

An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02985567
Enrollment
324
Registered
2016-12-07
Start date
2013-09-30
Completion date
2016-11-30
Last updated
2016-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Intraocular Pressure

Brief summary

The study involves a prospective evaluation of chloral hydrate sedation for the measurement of intraocular pressure in children ages one month to five years of age.

Detailed description

This study will be a prospective, non-randomized trial of children 1 month to 5 years of age who are determined to require a sedation procedure at the King Khaled Eye Specialist Hospital (KKESH). There will be two parts to the consent process. Oral consent will be administered to subjects who are not undergoing eye pressure evaluation. These children have chloral hydrate sedation for imaging or other eye evaluations. For these children, we will prospectively monitor the success rate of chloral hydrate sedation such that a complete ophthalmic or imaging evaluation could be performed and will determine the proportion of adverse events that occur due to sedation including vomiting, respiratory distress or depression, alterations in vital signs beyond reference ranges for normal sleeping children, hypoxia with oxygen saturation \<90%, and unplanned hospital admission. No testing will be performed for study purposes on these individuals. For children undergoing sedation who will have intraocular pressure measurements for clinical care purposes, we will perform additional eye pressure measurements as part of the research protocol. Written consent will be obtained to allow us to additionally measure their intraocular pressure as specified below. After recruitment and completion of informed consent procedures by parents, subjects' medical and ocular history will be reviewed by a study ophthalmologist and one of two pediatricians overseeing sedation procedures. Patients unable to undergo intraocular pressure measurement due to infection or ocular surface disease and those in whom chloral hydrate sedation is medically contraindicated will be excluded. Age, gender, diagnosis, current medications and surgical history will be recorded from the clinical chart for all subjects.

Interventions

OTHERIntraocular pressure evaluation

Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.

Sponsors

King Khaled Eye Specialist Hospital
CollaboratorOTHER_GOV
Johns Hopkins University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 5 Years
Healthy volunteers
No

Inclusion criteria

* ages 1 month to five years * require sedation for ophthalmic care

Exclusion criteria

* weight \<3 kg or \>20 kg * infection/ocular surface disease * medical contraindication of chloral hydrate * green or gray nasal discharge * fever, productive cough, chest retractions, or other signs of respiratory infection * oxygen saturation \< 90% * active infectious disease such as rubella or varicella * rectal or tympanic temperature \> 37.7 degrees, or oral or temporal artery temperature \> 37.2 degrees * history of current ongoing vomiting and diarrhea * anemia (Hgb \< 9.0mg), * history of seizure in past 6 weeks

Design outcomes

Primary

MeasureTime frameDescription
Change in intraocular pressure during chloral hydrate sedation25 minutes after sedation to 125 minutes after sedationUnit- mmHg

Secondary

MeasureTime frameDescription
Chloral hydrate dose required for successful sedationAdminstration to adequate sedation (up to 30 minutes)Unit- mg
Time to recoverySedation induction to 125 minutes after sedationUnit- minutes
Hear rate under sedationSedation induction to 125 minutes after sedationUnit- beats per minute
Blood pressure under sedationSedation induction to 125 minutes after sedationUnit- mmHg
Oxygen saturation under sedationSedation induction to 125 minutes after sedationUnit- %
Adverse events related to chloral hydrate sedationSedation induction to 125 minutes after sedationUnit- number of events (that occur from the following list) Vomiting, subclinical respiratory depression, recovery agitation, oxygen desaturation, airway obstruction, failed sedation, bradycardia, tachycardia, hypotension, hypertension, seizure, aspiration, apnea, arrhythmia, cardiac arrest Unit- number of events (that occur from the following list) Vomiting, subclinical respiratory depression, recovery agitation, oxygen desaturation, airway obstruction, failed sedation, bradycardia, tachycardia, hypotension, hypertension, seizure, aspiration, apnea, arrhythmia, cardiac arrest Unit- number of events (that occur from the following list) Vomiting, subclinical respiratory depression, recovery agitation, oxygen desaturation, airway obstruction, failed sedation, bradycardia, tachycardia, hypotension, hypertension, seizure, aspiration, apnea, arrhythmia, cardiac arrest

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026